Faricimab: Developing a Ophthalmologic Bispecific Therapeutic for AMD & DME

Time: 12:05 pm
day: Day Two

Details:

• Reviewing Ang-2 biology/Bispecific technology attributes
• Existing phase 3 trial designs
• Reviewing available clinical data

Speakers: